Abciximab contraindications

Doses and contraindications to glycoprotein Ilb/IIIa receptor blockers are described in Table 5-2. Major bleeding and rates of transfusion are increased with administration of a glycoprotein Ilb/IIIa receptor inhibitor in combination with aspirin and an anticoagulant,30 but there is no increased risk of intracranial hemorrhage in the absence of concomitant fibrinolytic treatment. The risk of thrombocytopenia with tirofiban and eptifibatide appears lower than that with abciximab. Bleeding risks appear similar between agents. 

In contrast to the putative superiority of abciximab in PCI, its role in medical stabilization therapy for ACS was seriously challenged by the findings of GUSTO-IV ACS trial, resulting in a Class III (contraindicated) recommendation. On the other hand, small molecules are recommended as Class II indication for medical management of ACS,... 

Abciximab is a glycoprotein Ilb/IIIa inhibitor and binds to glycoprotein Ilb/IIIA receptors on the surface of platelets, thereby preventing platelet aggregation. It is used as an adjunct to precutaneous coronary intervention (PCI) to prevent ischemic complications in patients at high risk of abrupt closure of the treated vessel. It is contraindicated in active internal bleeding. 

No. Oral anticoagulants are contraindicated. Abciximab should not be administered within 7 days of administration of an oral anticoagulant. 

---